Virginia Sanzone - ICU Medical Vice President General Counsel, Secretary
| ICUI Stock | USD 147.07 0.00 0.00% |
President
Ms. Virginia Sanzone is our Corporationrationrate Vice President, General Counsel and Secretary since January 2018. Ms. Sanzone also serves as our Compliance Officer since 2018.
| Age | 50 |
| Tenure | 7 years |
| Address | 951 Calle Amanecer, San Clemente, CA, United States, 92673 |
| Phone | 949 366 2183 |
| Web | https://www.icumed.com |
ICU Medical Management Efficiency
The company has return on total asset (ROA) of 0.0142 % which means that it generated a profit of $0.0142 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0576) %, meaning that it created substantial loss on money invested by shareholders. ICU Medical's management efficiency ratios could be used to measure how well ICU Medical manages its routine affairs as well as how well it operates its assets and liabilities. The ICU Medical's current Return On Tangible Assets is estimated to increase to -0.06. The current Return On Capital Employed is estimated to decrease to 0.01. As of now, ICU Medical's Total Current Assets are increasing as compared to previous years. The ICU Medical's current Other Current Assets is estimated to increase to about 363.3 M, while Net Tangible Assets are forecasted to increase to (373.7 M).Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Brian Andrews | The Cooper Companies, | 45 | |
| Joseph Wright | Merit Medical Systems | 55 | |
| Kim Seabury | AngioDynamics | 58 | |
| Xiangwei Gong | AptarGroup | 54 | |
| Jacqueline Scanlan | Haemonetics | 46 | |
| Daniel McBride | The Cooper Companies, | 56 | |
| Warren Nighan | AngioDynamics | 56 | |
| Robert Kuhn | AptarGroup | 63 | |
| James Darecca | Haemonetics | 50 | |
| Eldon Schaffer | AptarGroup | 53 | |
| Justin Noznesky | AtriCure | 47 | |
| Michelle Basil | Haemonetics | 52 | |
| Hedi Tlili | AptarGroup | 49 | |
| Howard Yu | Envista Holdings Corp | 51 | |
| Anila Lingamneni | Haemonetics | 57 | |
| Gael Touya | AptarGroup | 55 | |
| Roy Galvin | Haemonetics | 54 | |
| Robert Auerbach | The Cooper Companies, | 58 | |
| Jan Verstreken | Hologic | 57 | |
| Pascal Bamford | Akoya Biosciences | N/A | |
| Jeffrey Kappler | Envista Holdings Corp | 41 | |
Management Performance
| Return On Equity | -0.0576 | ||||
| Return On Asset | 0.0142 |
ICU Medical Leadership Team
Elected by the shareholders, the ICU Medical's board of directors comprises two types of representatives: ICU Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ICU. The board's role is to monitor ICU Medical's management team and ensure that shareholders' interests are well served. ICU Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ICU Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Virginia Sanzone, Vice President General Counsel, Secretary | ||
| Clay Fradd, Corporate Resources | ||
| Christian Voigtlander, Chief Officer | ||
| Brian Bonnell, CFO Treasurer | ||
| Vivek Jain, Chairman and CEO | ||
| Daniel Woolson, President |
ICU Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ICU Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0576 | ||||
| Return On Asset | 0.0142 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 4.94 B | ||||
| Shares Outstanding | 24.52 M | ||||
| Shares Owned By Insiders | 7.83 % | ||||
| Shares Owned By Institutions | 99.80 % | ||||
| Number Of Shares Shorted | 786.38 K | ||||
| Price To Earning | 38.71 X |
Currently Active Assets on Macroaxis
When determining whether ICU Medical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ICU Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Icu Medical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Icu Medical Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ICU Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more detail on how to invest in ICU Stock please use our How to Invest in ICU Medical guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ICU Medical. If investors know ICU will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ICU Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.24) | Earnings Share (4.82) | Revenue Per Share | Quarterly Revenue Growth 0.071 | Return On Assets |
The market value of ICU Medical is measured differently than its book value, which is the value of ICU that is recorded on the company's balance sheet. Investors also form their own opinion of ICU Medical's value that differs from its market value or its book value, called intrinsic value, which is ICU Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ICU Medical's market value can be influenced by many factors that don't directly affect ICU Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ICU Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if ICU Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ICU Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.